A class action lawsuit has been filed against Ardelyx, Inc. for allegedly misleading investors about the commercial performance and growth prospects of its key drugs, IBSRELA and XPHOZAH, between January 2025 and August 2026. The lawsuit claims Ardelyx concealed increasing payer restrictions and barriers that slowed patient access, causing investors to buy shares at inflated prices. The stock price fell 18% after Ardelyx cut its 2026 revenue guidance and withdrew long-term growth forecasts due to market challenges. Investors who bought Ardelyx stock during this period may be eligible to join the lawsuit before the November 16, 2026 deadline.
The class action lawsuit against Ardelyx, Inc. is presented here with a snapshot of the Health sector on Pluang as of Sep 22, 2026 01:32 WIB: out of 95 priced US health stocks, 62 rose and 32 fell. Among notable movers, ADMA Biologics Inc gained 4.50% at USD 9.52 with 100% buy orders and a typical hold time of 17 days, while Crispr Therapeutics AG rose 4.03% to USD 58.84 with 72% buy orders and a longer hold time of 76 days. Aurora Cannabis Inc also increased 4.01% to USD 4.03, fully supported by buy orders and a 26-day hold time.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Fannie Mae completed its 28th sale of non-performing loans, selling 919 loans totaling $203.3 million in unpaid principal to Residential Credit Opportunities Trust IX-D. The loans have an average size of $221,222 and a weighted average interest rate ...
SanDisk shares fell 2% while the broader memory sector, including peers Micron and Western Digital, saw gains of 3% and 0.8% respectively. This divergence occurred without any company-specific news, suggesting profit-taking or position trimming after...
Jim Cramer recommends investors to "own it, don't trade it" for Apple and NVIDIA, emphasizing long-term holding over short-term trading. Both companies are competing for the title of the world's most valuable publicly traded company, with NVIDIA lead...
Opendoor Technologies' stock fell 24% over the past month despite a 5% gain in recent trading, underperforming peers like Offerpad and Zillow. The decline reflects broader housing market challenges, including rising mortgage rates that increase finan...
